High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE‐hypermutated colorectal cancers

Bibliographic Details
Title: High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE‐hypermutated colorectal cancers
Authors: Loetitia Favre, Justine Cohen, Julien Calderaro, Adrien Pécriaux, Cong‐Trung Nguyen, Rémi Bourgoin, Laura Larnaudie, Aurélie Dupuy, Marie Ollier, Emmanuèle Lechapt, Ivan Sloma, Christophe Tournigand, Benoit Rousseau, Anaïs Pujals
Source: Molecular Oncology, Vol 16, Iss 17, Pp 3055-3065 (2022)
Publisher Information: Wiley, 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: colorectal cancers, immunotherapy, POLE, polymerase epsilon, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Exonucleasic domain POLE (edPOLE) mutations, which are responsible for a hypermutated tumor phenotype, occur in 1–2% of colorectal cancer (CRC) cases. These alterations represent an emerging biomarker for response to immune checkpoint blockade. This study aimed to assess the molecular characteristics of edPOLE‐mutated tumors to facilitate patient screening. Based on opensource data analysis, we compared the prevalence of edPOLE mutations in a control group of unselected CRC patients (n = 222) vs a group enriched for unusual BRAF/RAS mutations (n = 198). Tumor mutational burden (TMB) and immune infiltrate of tumors harboring edPOLE mutations were then analyzed. In total, 420 CRC patients were analyzed: 11 edPOLE‐mutated tumors were identified, most frequently in microsatellite (MMR)‐proficient young (
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1878-0261
1574-7891
Relation: https://doaj.org/toc/1574-7891; https://doaj.org/toc/1878-0261
DOI: 10.1002/1878-0261.13257
Access URL: https://doaj.org/article/de57e5bff1614f3a8b7c4347a9846920
Accession Number: edsdoj.57e5bff1614f3a8b7c4347a9846920
Database: Directory of Open Access Journals
More Details
ISSN:18780261
15747891
DOI:10.1002/1878-0261.13257
Published in:Molecular Oncology
Language:English